The short answer — and why it depends on your diagnosis

Yes — in the right clinical picture, cartilage repair can meaningfully delay or, in some cases, help avoid knee replacement altogether. The critical qualifier is the diagnosis sitting behind that question.

Cartilage repair is designed for a focal defect: a discrete, localised lesion in the articular surface of an otherwise reasonable joint. Think of it as a pothole in an otherwise sound road. Diffuse osteoarthritis, by contrast, is the whole road surface worn away — and no amount of targeted patching restores a joint that has lost cartilage broadly across the compartment. These are genuinely different clinical scenarios, and the distinction determines whether repair is on the table at all.

When the diagnosis is a symptomatic focal defect, the long-term data are genuinely encouraging. A systematic review of matrix-associated autologous chondrocyte implantation (MACI) with follow-up exceeding ten years found that only 7.4% of patients ultimately progressed to total knee arthroplasty — a notably low conversion rate. The supporting principle is biological: repair works best while healthy surrounding cartilage remains. Articular cartilage has very poor capacity to regenerate on its own, so the window for intervention narrows as arthritis advances.

The sections below explain which procedures are available, who is likely to benefit, and what the evidence actually shows about outcomes — so patients and their clinicians can judge which pathway fits the clinical picture.

Who is a realistic candidate for cartilage repair

Several variables determine whether a patient sits within the scope of cartilage repair, and clarifying them early helps direct the right clinical conversation.

Age and activity level are the starting point. Cartilage repair — from osteochondral grafting to cell-based implantation — is generally most appropriate for younger, active patients with specific, isolated cartilage injuries. The biology of tissue regeneration is more responsive in that context; as degenerative change advances and the surrounding joint environment deteriorates, the conditions for successful repair become less favourable.

Defect morphology is the primary structural criterion. Focal, contained lesions graded ICRS III or IV — full-thickness damage within discrete margins, with reasonably healthy surrounding cartilage — respond considerably better than uncontained or diffuse lesions. Intact cartilage around the defect perimeter gives the repair tissue something to integrate into; that architecture is absent in widespread degeneration.

Lower-limb alignment requires assessment alongside any defect evaluation. Varus or valgus malalignment concentrates load through specific compartments, effectively loading a repaired patch unevenly and shortening its functional life. Where malalignment is present, osteotomy to redistribute joint load is often considered in combination with a cartilage procedure rather than as an afterthought.

Meniscal integrity operates through the same mechanical logic. A meniscal-deficient compartment carries greater contact stress; without addressing that, the durability of any cartilage repair is compromised from the outset.

Patients with established, diffuse osteoarthritis across a compartment fall outside the scope of these procedures. For that group, the appropriate conversation shifts to joint preservation planning or replacement — a different pathway, but an equally important one. A thorough assessment of the full joint environment, covering all four of these variables, is the standard starting point before any repair option is confirmed.

The non-surgical pathway that comes first

Before any surgical repair is considered, a structured programme of non-surgical management comes first — not as a procedural hurdle, but because reducing joint load and strengthening the surrounding musculature genuinely alters the mechanical environment in which a focal defect sits.

Weight management and low-impact exercise are the foundation. Reducing body mass lowers compressive force through the knee with every step; swimming and cycling maintain cardiovascular fitness and muscle mass without the impact loading that aggravates cartilage pain.

Physiotherapy targets the muscles that govern load distribution — specifically quadriceps strength and hip-abductor control. Weakness in either group shifts mechanical stress unevenly across the joint surface, accelerating symptom progression even in a contained defect.

Intra-articular injections play a supporting role at this stage. Corticosteroids can settle acute inflammatory flares; viscosupplementation (hyaluronic acid) and platelet-rich plasma (PRP) offer meaningful pain and function improvements in many patients. It is worth being clear, however, that neither HA nor PRP regenerates cartilage structurally — their benefit is symptomatic, and that distinction matters when setting expectations.

Unloader bracing can mechanically offload the affected compartment without any procedure, and may defer the need for intervention in patients with early compartmental loading.

The NHS pathway formalises this sequence: non-surgical options are expected to be attempted before surgical alternatives are offered. If pain remains functionally limiting despite an adequate trial — typically months, not weeks — that is usually the signal that the surgical pathway warrants discussion.

Matching the repair technique to the defect

Defect size is the primary decision branch when a consultant maps a cartilage lesion to a repair option. Alongside it, a technique's stage requirements, recovery profile, and evidence base all factor in — but size provides the initial framework.

Smaller defects (roughly under 2 cm²)

For contained focal lesions at the smaller end of the spectrum, OATS (osteochondral autograft transfer) or mosaicplasty offers a single-stage solution: a cylinder of healthy cartilage and underlying bone is harvested from a lower-load area of the knee and transplanted into the defect. Long-term follow-up data support meaningful durability with this approach.

Microfracture has historically been used for smaller lesions — it creates tiny perforations in the subchondral bone to trigger a fibrocartilage-forming 'super-clot'. Current evidence shows, however, that fibrocartilage tends to break down at roughly two to three years, and the procedure can damage the subchondral bone plate in ways that complicate future repair. It is therefore no longer considered a preferred first-line option, though patients who have undergone it previously will encounter it when reviewing their history.

Intermediate to larger defects (2–10 cm²)

For lesions in this range, MACI (matrix-induced autologous chondrocyte implantation) carries the strongest evidence base. The SUMMIT RCT found that for defects of 3 cm² or more, MACI delivered significantly better KOOS pain and function scores than microfracture at both two and five years. The trade-off is a two-stage commitment: an initial biopsy to harvest and culture the patient's own chondrocytes, followed by implantation of a cell-seeded collagen membrane.

AMIC (autologous matrix-induced chondrogenesis) sits between these approaches — a single-stage procedure that combines marrow stimulation with a scaffold matrix, with an intermediate evidence base for patients where a two-stage pathway is not suitable.

An outpatient injectable pathway

For suitable focal defects up to approximately 3 cm² — extendable to 6 cm² in some cases — ChondroFiller injection offers a minimally invasive alternative delivered as an ultrasound-guided, outpatient injectable collagen scaffold, without the theatre setting or two-stage process that ACI and MACI require. The scaffold recruits the patient's own progenitor cells to initiate matrix-induced chondrogenesis at the defect site.

Selecting between these options requires assessment of the full clinical picture, including defect morphology, alignment, and prior interventions. The MSK Doctors team evaluates suitability across this full range, matching technique to defect rather than applying a single default pathway.

Why alignment correction can make or break cartilage repair

Repairing a focal cartilage lesion while leaving the knee in the wrong alignment is rather like filling a pothole on a road that is still cambered the wrong way — the repair carries abnormal load from the moment it is complete, and early failure becomes predictable rather than unlikely.

High tibial osteotomy (HTO) corrects a varus, or bow-legged, deformity by reshaping the upper tibia to shift weight-bearing load away from the diseased medial compartment. Distal femoral osteotomy (DFO) addresses the less common valgus, or knock-kneed, alignment by correcting the femoral angle. Both can be performed as day or short-stay cases and, depending on the degree of correction needed and the state of the cartilage, both can be combined with cartilage repair in the same episode or arranged in a staged sequence.

Where a younger patient has unicompartmental loading and early OA but the cartilage defect is too advanced for restoration alone, osteotomy may function as a standalone joint-preservation strategy — improving function and comfort for a meaningful period without committing to joint replacement.

Two further joint-environment factors operate on the same principle. Meniscal pathology — as covered in the candidate-selection section above — concentrates compartmental load on any repair site and should be incorporated into the treatment plan rather than deferred. Ligament instability, particularly ACL deficiency, introduces shear forces that maturing repair tissue cannot withstand; where instability is identified, ligament reconstruction is often part of the same staged plan.

The common thread across all three factors is that cartilage repair does not exist in isolation. Addressing alignment, meniscal integrity, and ligamentous stability is what allows the repair to function in the environment it was designed for.

What the evidence realistically shows — and where uncertainty remains

The outcomes data from well-conducted cartilage repair series are genuinely encouraging — but reading them accurately requires understanding where those numbers come from and what they cannot tell us.

What the evidence does establish

The conversion figures discussed earlier in this article derive from studies that selected patients carefully: younger, active individuals with focal, isolated lesions and normal or corrected alignment. That selection is clinically appropriate, and the results are meaningful. They do not, however, describe what happens when cartilage repair is applied to the broader arthritic knee population. For patients outside those parameters — older individuals, those with diffuse OA, concurrent malalignment, or meniscal deficiency — outcomes are less predictable and the supporting evidence is thinner.

There is also no head-to-head randomised controlled trial that has measured 'years of TKR delay' as its primary endpoint. The delay inference comes from conversion rates — the proportion of patients who have not required a replacement at a given follow-up point — rather than from a direct time-to-replacement comparison. That does not undermine the evidence, but it is worth stating plainly.

Where uncertainty remains

Scaffold-based approaches carry promising early data but have shorter follow-up periods and smaller trial populations than the established cell-based techniques. The picture continues to develop as longer series accumulate.

Intra-articular biologics such as PRP and viscosupplementation provide genuine symptomatic benefit but do not regenerate structural cartilage — their role is to reduce pain and modify the joint environment, not to restore the articular surface itself.

The practical implication of the evidence is that available options narrow as joint degeneration advances — which is why early specialist assessment of a symptomatic focal defect tends to leave more pathways open.

1. [1] Knee Cartilage Replacement Therapy. https://en.wikipedia.org/?curid=4984243 https://en.wikipedia.org/?curid=4984243
2. [2] Autologous Chondrocyte Implantation. https://en.wikipedia.org/?curid=19074150 https://en.wikipedia.org/?curid=19074150
3. [3] Microfracture Surgery. https://en.wikipedia.org/?curid=8840994 https://en.wikipedia.org/?curid=8840994